GS-7340 hemifumarate

For research use only. Not for therapeutic Use.

  • CAT Number: I001502
  • CAS Number: 1392275-56-7
  • Molecular Formula: C21H29N6O5P.1/2 C4H4O4
  • Molecular Weight: 534.50
  • Purity: ≥95%
Inquiry Now

GS-7340 Hemifumarate(Cat No.:I001502)is the hemifumarate salt form of GS-7340, an investigational nucleotide reverse transcriptase inhibitor (NRTI) used in the treatment of HIV. As a prodrug, GS-7340 is converted in the body to the active metabolite tenofovir, which inhibits the reverse transcriptase enzyme, essential for viral replication. GS-7340 has shown potent anti-HIV activity and is included in combination therapies. Its hemifumarate form enhances bioavailability and stability, making it an important candidate for HIV treatment, offering a long half-life and effective viral suppression.


Catalog Number I001502
CAS Number 1392275-56-7
Molecular Formula C21H29N6O5P.1/2 C4H4O4
Purity ≥95%
Target HIV
Solubility DMSO
Storage Store at RT
IUPAC Name (E)-but-2-enedioic acid;propan-2-yl (2S)-2-[[[(2R)-1-(6-aminopurin-9-yl)propan-2-yl]oxymethyl-phenoxyphosphoryl]amino]propanoate
InChI InChI=1S/2C21H29N6O5P.C4H4O4/c2*1-14(2)31-21(28)16(4)26-33(29,32-17-8-6-5-7-9-17)13-30-15(3)10-27-12-25-18-19(22)23-11-24-20(18)27;5-3(6)1-2-4(7)8/h2*5-9,11-12,14-16H,10,13H2,1-4H3,(H,26,29)(H2,22,23,24);1-2H,(H,5,6)(H,7,8)/b;;2-1+/t2*15-,16+,33+;/m11./s1
InChIKey SVUJNSGGPUCLQZ-FQQAACOVSA-N
SMILES C[C@H](CN1C=NC2=C(N=CN=C21)N)OC[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC3=CC=CC=C3.C[C@H](CN1C=NC2=C(N=CN=C21)N)OC[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC3=CC=CC=C3.C(=C/C(=O)O)\C(=O)O
Reference

<p style=/line-height:25px/>
<br>[1]. Birkus G, et al. Intracellular Activation of Tenofovir Alafenamide and the Effect of Viral and Host Protease Inhibitors. Antimicrob Agents Chemother. 2015 Oct 26;60(1):316-22.

<br>[2]. Callebaut C, et al. In Vitro Virology Profile of Tenofovir Alafenamide, a Novel Oral Prodrug of Tenofovir with Improved Antiviral Activity Compared to That of Tenofovir Disoproxil Fumarate. Antimicrob Agents Chemother. 2015 Oct;59(10):5909-16.

</p>

Request a Quote